Roche Blocks Indian Trastuzumab; Says No Room For ''Uncertainty''

Roche has moved to block Reliance Life Sciences Pvt Ltd's biosimilar version of its anticancer Herceptin (trastuzumab) in India citing "genuine" concern over the comparable safety and efficacy of the Indian firm's product.